UNSOED Conferences, “4th International Conference In Health Sciences (ICHS)”

Font Size: 
POST IMMUNIZATION EVENTS (AEFI) POST VACINATION OF COVID-19 OBSERVED FROM COMORBID ON HEALTH PERSONNEL AND PUBLIC SERVICES
wiwik utami

Last modified: 2021-08-09

Abstract


POST IMMUNIZATION EVENTS (AEFI)  POST VACINATION OF COVID-19 OBSERVED FROM COMORBID ON HEALTH PERSONNEL AND PUBLIC SERVICES

Wiwik Utami1, Rahmawati2, Siti Patonah3, Imam Wahyudi4)

1,2,3)Institute Health Rajekwesi of Bojonegoro,4)Bojonegoro district health office


ABSTRACT


Since being declared a pandemic in March 2020 by WHO, Covid-19 has claimed millions of lives worldwide. The last effort in dealing with the Covid-19 pandemic is through vaccination with the first target being health workers and public servants. The main challenge in this vaccination program is negative hoaxes, and post-immunization events (AEFI). Comorbid sufferers are a group at risk of being exposed to the severity of Covid-19. Vaccination raises both hope and concern about the effectiveness of the Covid-19 vaccine. The purpose of this study was to explore AEFIs as well as to analyze the correlational incidence of AEFI in comorbid patients in health workers and public servants.

The research design was correlational analytic with cross sectional approach. The population is all health personnel and public servants in Bojonegoro Regency who are at least 18 years old who were netted in social media with a sample size of 262 and were taken using accidental sampling technique. The research instrument was a questionnaire using google form. Univariate analysis is presented in the form of presentation while the bivariate analysis uses the Chi Square test with a significance of α 0.05.

The results showed that from 262 respondents, 74.8% were not comorbid, 25.2% were comorbid. The incidence of AEFI was 56.9% with a relatively even occurrence after vaccination I, II, I and II. An AEFI started 40.1% within 24 hours post vaccination with a 48.7% symptom duration within 1-24 hours.  AEFI reactions 42.3% are other reactions in the form of allergic reactions, drowsiness and increased appetite. The correlation between comorbid conditions and the incidence of AEFI showed a p-value of 0.894, meaning that both comorbid and non-comorbid patients had the same risk of developing AEFI.

Comorbid or non-comorbid is safe to get Covid-19 vaccination. Supervisor, reporting on AEFI is important to anticipate the condition of severity. Health protocols must continue to be implemented because vaccination does not protect 100% but is an effort to reduce the risk of being exposed to Covid-19